Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) announced completion of enrollment in its Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE